The Use of Omalizumab in Food Oral Immunotherapy

30Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

Food allergy is an important health issue that affects up to 8 % of the population. The management of allergic patients involves allergen avoidance and prompts the treatment of accidental reactions, as no curative treatment is available so far in routine practice. Oral immunotherapy (OIT) is a promising therapeutic alternative, but it is associated with frequent allergic reactions and cost-effectiveness issues. In hopes of reducing such reactions, a number of trials have used omalizumab, an anti-IgE monoclonal humanized antibody, as adjunctive therapy in OIT. The allergens studied in these omalizumab-enabled OIT trials include peanuts, milk, eggs, or mixes of multiple foods. In this article, we review the major findings from these studies and discuss potential benefits and issues related to omalizumab-enabled OIT. Results from the previous trials suggest that the use of omalizumab could potentially lead to safer and more efficient OIT protocols, by reducing the number and severity of reactions, and increasing allergen tolerance threshold. While more evidence is needed with regard to the maintenance of the long-term tolerance after OIT, omalizumab’s potential immunomodulatory role could be of benefit. More studies are needed to further document this new indication for omalizumab.

Cite

CITATION STYLE

APA

Labrosse, R., Graham, F., Des Roches, A., & Bégin, P. (2017, June 1). The Use of Omalizumab in Food Oral Immunotherapy. Archivum Immunologiae et Therapiae Experimentalis. Birkhauser Verlag AG. https://doi.org/10.1007/s00005-016-0420-z

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free